ω-3 fatty acids and lutein+zeaxanthin supplementation for the prevention of cardiovascular disease

JAMA Internal Medicine

Volumn 174, Issue 5, 2014, Pages 771-772

  Rizos, Evangelos C ^a   Ntzani, Evangelia E ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NON PRESCRIPTION DRUG; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; XANTHOPHYLL; ZEAXANTHIN;

ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG MEGADOSE; EUROPEAN MEDICINES AGENCY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INTENTION TO TREAT ANALYSIS; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; RISK REDUCTION; SUDDEN DEATH; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LUTEIN; MACULAR DEGENERATION; MALE; XANTHOPHYLLS;

EID: 84897137225     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.13734     Document Type: Note

References (8)

1. Research and Markets. Omega-3 Marine And Plant Products: Global Markets, Competitors And Opportunities: 2013-2018 Analysis and Forecasts. July 2013. http://www.researchandmarkets.com /research/dfz3h3/omega3-marine. Accessed January 30, 2014.
2. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540-550.
3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 7, 2013]. J AmColl Cardiol. doi:10.1016/j.jacc.2013.11.002.
4. Food and Drug Administration. Lovaza: GlaxoSmithKline. http://www.accessdata.fda.gov /drugsatfda-docs/label/2012/021654s034lbl.pdf. Accessed February 11, 2014.
5. Electronic Medicines Compendium. Omacor: Abbott Healthcare Products Limited. http://www.medicines.org.uk/emc/medicine/10312 /indications. Accessed February 11, 2014.
6. Writing Group for the AREDS2 Research Group. Effect of long-chain ?-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial [published online March 17, 2014]. JAMA Intern Med. doi:10.1001/ jamainternmed.2014.328.
7. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.
8. Roncaglioni MC, Tombesi M, Avanzini F, et al; Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800-1808.